Novavido
NOVAVIDO: THE START-UP THAT WILL STUDY THE FIRST LIQUID ARTIFICIAL RETINA IN HUMANS
A start-up of the Italian Institute of Technology (IIT) in which Utopia has invested together with AlfaSigma, Fondazione Chiossone, and Club 2021.
The financial and technological intervention provided by AlfaSigma is a project concerning the development of an injectable and biocompatible device called ‘liquid retina,’ which would enable partial vision recovery for individuals affected by partial blindness caused by degenerative retinal diseases.
The research has been developed over a period of 10 years by the Center for Nano Science and Technology (CNST-IIT Milan) led by Guglielmo Lanzani and the Center for Synaptic Neuroscience and Technology (NSYN-IIT Genoa) led by Fabio Benfenati, in collaboration with Grazia Pertile and Maurizio Mete from the IRCCS Ospedale Sacro Cuore Don Calabria in Negrar (Verona). Novavido S.r.l. is a start-up accelerated within the G-Factor incubator of Fondazione Golinelli.
Utopia invested in 2021.
